HMR59 : Janssen acquires rights to geographic atrophy treatment candidate from Hemera
Geographic atrophy treatment : Janssen Pharmaceuticals has signed a licensing deal to acquire rights to HMR59, an investigational gene therapy for geographic atrophy, from clinical stage ocular gene therapy company Hemera Biosciences for an undisclosed price. HMR59 is intended to be given as a one-time, outpatient, intravitreal injection for helping in preserving vision in patients […]